干细胞来源全分化胰岛细胞治疗1型糖尿病
这项1-2期研究评估了同种异体干细胞来源胰岛细胞疗法zimislecel在1型糖尿病患者中的安全性和疗效。14例受试者接受半剂量或全剂量单次门静脉输注,所有受试者均实现胰岛植入和功能,12例全剂量受试者均无严重低血糖事件且糖化血红蛋白低于7%,10例(83%)在第365天实现胰岛素不依赖。结论认为这项小型短期研究支持zimislecel可恢复生理性胰岛功能的假设,需进一步临床研究。
要点
- 14例受试者输注后均检测到C肽,提示胰岛植入和功能恢复。
- 12例全剂量受试者均无严重低血糖事件,糖化血红蛋白低于7%。
- 10/12(83%)受试者在第365天实现胰岛素不依赖。
核心结论
- 这项小型短期研究结果支持zimislecel可恢复生理性胰岛功能的假设,需进一步临床研究。
研究设计与样本
- 1-2期研究,A部分受试者接受半剂量zimislecel(0.4×10^9个细胞)单次门静脉输注,可选择2年内再次接受半剂量;B和C部分受试者接受全剂量zimislecel(0.8×10^9个细胞)单次输注。
- 所有受试者均接受无糖皮质激素的免疫抑制治疗。
- 共14例受试者(A部分2例,B和C部分12例)完成至少12个月随访并纳入分析。
主要发现
- 14例受试者基线时C肽均不可测,输注zimislecel后所有受试者均检测到C肽,提示胰岛植入和功能。
- 12例B和C部分受试者均无严重低血糖事件,糖化血红蛋白均低于7%,处于目标血糖范围(70-180 mg/dL)的时间超过70%。
- 12例中10例(83%)在第365天实现胰岛素不依赖且未使用外源性胰岛素。
- 中性粒细胞减少是最常见的严重不良事件,发生于3例受试者。
- 发生2例死亡,一例死于隐球菌性脑膜炎,一例死于严重痴呆伴激越,源于既存神经认知障碍的进展。
关键数值与推荐
- A部分主要终点为安全性。
- C部分主要终点为第90至365天无严重低血糖事件,且第180至365天至少一个时间点糖化血红蛋白低于7%或较基线下降至少1个百分点。
- C部分次要终点包括第180至365天的安全性和胰岛素不依赖。
- 采用4小时混合餐耐量试验中血清C肽检测评估植入和胰岛功能。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文自述为小型、短期研究。
- 所有分析均为期中分析且非预设。
- 原文结论提出需进一步临床研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Zimislecel is an allogeneic stem cell-derived islet-cell therapy. Data on the safety and efficacy of zimislecel in persons with type 1 diabetes are needed. METHODS: We conducted a phase 1-2 study of zimislecel in persons with type 1 diabetes. In part A, participants received a half dose of zimislecel (0.4 × 109 cells) as a single infusion into the portal vein, with an option for a second half dose within 2 years. In parts B and C, participants received a full dose of zimislecel (0.8 × 109 cells) as a single infusion. All the participants also received glucocorticoid-free immunosuppressive therapy. The primary end point in part A was safety. The primary end point in part C was freedom from severe hypoglycemic events during days 90 through 365, with a glycated hemoglobin level of less than 7% or a decrease of at least 1 percentage point from baseline in the glycated hemoglobin level at one or more time points between days 180 and 365. Secondary end points in part C included safety and insulin independence between days 180 and 365. Assessment of the primary and secondary end points in part C involved the participants who received the full dose of zimislecel as a single infusion in part B or C. Detection of serum C-peptide during a 4-hour mixed-meal tolerance test was used to assess engraftment and islet function. All the analyses were interim and not prespecified. RESULTS: A total of 14 participants (2 in part A and 12 in parts B and C) completed at least 12 months of follow-up and were included in the analyses. C-peptide was undetectable at baseline in all 14 participants. After zimislecel infusion, all the participants had engraftment and islet function, as evidenced by the detection of C-peptide. Neutropenia was the most common serious adverse event, occurring in 3 participants. Two deaths occurred - one caused by cryptococcal meningitis and one by severe dementia with agitation owing to the progression of preexisting neurocognitive impairment. All 12 participants in parts B and C were free of severe hypoglycemic events and had a glycated hemoglobin level of less than 7%; these participants spent more than 70% of the time in the target glucose range (70 to 180 mg per deciliter). Ten of the 12 participants (83%) had insulin independence and were not using exogenous insulin at day 365. CONCLUSIONS: The results of this small, short-term study involving persons with type 1 diabetes support the hypothesis that zimislecel can restore physiologic islet function, warranting further clinical investigation. (Funded by Vertex Pharmaceuticals; VX-880-101 FORWARD ClinicalTrials.gov number, NCT04786262.).
引用
- Reichman TW, Markmann JF, Odorico J, et al. Stem Cell-Derived, Fully Differentiated Islets for Type 1 Diabetes. N Engl J Med. 2025. PMID: 40544428. doi:10.1056/NEJMoa2506549
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。